Jade Biosciences (JBIO) Change in Accured Expenses (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Change in Accured Expenses data on file, last reported at $5.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 396.3% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (up 306.98% YoY) and the FY2025 annual result came in at $3.9 million, up 2319.63% from the prior year.
• Change in Accured Expenses grew to $5.8 million in Q1 2026, from -$3.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $10.1 million in Q4 2023 to a low of -$3.5 million in Q4 2025.
• A 5-year average of $1.3 million and a median of $590000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 5257.14% in 2022, down 6648.15% in 2022.
• Tracing JBIO's Change in Accured Expenses over 5 years: stood at -$1.8 million in 2022, then surged by 672.0% to $10.1 million in 2023, then sank by 60.64% to $4.0 million in 2024, then plunged by 187.84% to -$3.5 million in 2025, then surged by 265.1% to $5.8 million in 2026.
• The last three Change in Accured Expenses figures came in at $5.8 million (Q1 2026), -$3.5 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.